Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
February 2019
-
In The NewsNovartis is flipping the pyramid, explains Steven BaertIn this episode of CNN`s special HR series, Steven Baert, Chief People & Organization Officer, shares the challenges that Novartis is facing as it turns its management style on its head and…
-
How a 19th-century technology is speeding up drug discovery
Pneumatic tube systems have existed for 150+ years and have transported everything from telegrams to aircraft parts. Now they’re being used in our labs.
-
Key ReleaseNovartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-offBasel, February 25, 2019 - Novartis today published certain key financial information for the Alcon eye care business covering the full year 2018 ahead of a vote on the proposed 100% spin-off of…
-
Media ReleaseNovartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a)Novartis announced today that it is exercising its option to license the rights to develop and commercialize TQJ230, an investigational agent previously known as AKCEA-APO(a)-LRx, from Akcea…
-
Media ReleaseNovartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical diseaseEgaten is the only drug approved in the US for the treatment of people with fascioliasis and is currently the only treatment recommended by the WHO Fascioliasis, commonly known as liver…
January 2019
-
Featured NewsNovartis 2018 Financial ResultsNovartis CEO Vas Narasimhan announced the company’s fourth quarter and 2018 full year results.
-
Key ReleaseNovartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018Full year net sales up 5% (cc[1], +6% USD) driven by strong performance of growth drivers: Pharmaceuticals BU grew 7% (cc) driven by Cosentyx USD 2.8 billion (+36% cc) and Entresto USD 1.0…
-
Key ReleaseEn 2018, Novartis a enregistré une forte croissance de ses ventes, avec une expansion de sa marge core, développé des plates-formes leaders de traitements de pointe, et recentré l'entrepriseHausse du chiffre d'affaires net de 5% (tcc[1], +6% USD) en 2018, soutenue par l'excellente performance des moteurs de croissance: Pharmaceuticals: cette unité opérationnelle a progressé de 7% (…
-
Key ReleaseNovartis erzielt 2018 ein kräftiges Umsatzwachstum bei gleichzeitiger Steigerung der Kerngewinnmarge, baut wegweisende Therapie¬plattformen auf und fokussiert das UnternehmenDer Nettoumsatz steigt im Geschäftsjahr um 5% (kWk[1], +6% USD) dank starker Performance der Wachstumstreiber: Die Geschäftseinheit Pharmaceuticals wächst um 7% (kWk), getragen von Cosentyx mit…
-
In The NewsFortune's Most Admired Pharmaceutical Companies 2019Novartis ranks #4 in Fortune Magazine’s Most Admired Companies Pharmaceutical Industry list.
-
In The NewsThe Science and Business of Innovative MedicinesIn this a16z podcast, bio general partners Jorge Conde and Vijay Pande with Sonal Chokshi interview Vas Narasimhan, CEO of Novartis, on some questions, challenges and opportunities that we’re facing…
-
Media ReleaseNovartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell diseaseCrizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease Sickle cell VOCs, which are…
Pagination
- ‹ Previous page
- 1
- …
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- …
- 152
- › Next page